Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Non-adherence to antimicrobial stewardship prospective audit and feedback advice: Risk factors and clinical consequences.

Horton CD, Rawlins MDM, Manning L, Ingram PR.

J Infect Chemother. 2019 Jun;25(6):485-488. doi: 10.1016/j.jiac.2019.02.011. Epub 2019 Mar 20.

PMID:
30904463
2.

Managing diabetic foot infections: a survey of Australasian infectious diseases clinicians.

Commons RJ, Raby E, Athan E, Bhally H, Chen S, Guy S, Ingram PR, Lai K, Lemoh C, Lim LL, Manning L, Miyakis S, O'Reilly M, Roberts A, Sehu M, Torda A, Vicaretti M, Lazzarini PA.

J Foot Ankle Res. 2018 Apr 10;11:13. doi: 10.1186/s13047-018-0256-3. eCollection 2018.

3.

Successful outpatient parenteral antibiotic therapy delivery via telemedicine.

Tan SJ, Ingram PR, Rothnie AJ, Whitmore TJ, Robinson JO, Hatch JB, Italiano CM, Heath CH.

J Antimicrob Chemother. 2017 Oct 1;72(10):2898-2901. doi: 10.1093/jac/dkx203.

PMID:
29091189
4.

Optimizing adherence to advice from antimicrobial stewardship audit and feedback rounds.

Rawlins MDM, Sanfilippo FM, Ingram PR, McLellan DGJ, Crawford C, D'Orsogna L, Dyer J.

J Chemother. 2018 Feb;30(1):59-62. doi: 10.1080/1120009X.2017.1336318. Epub 2017 Jun 5.

PMID:
28580878
5.

Phylogenetic diversity, antimicrobial susceptibility and virulence characteristics of phylogroup F Escherichia coli in Australia.

Vangchhia B, Abraham S, Bell JM, Collignon P, Gibson JS, Ingram PR, Johnson JR, Kennedy K, Trott DJ, Turnidge JD, Gordon DM.

Microbiology. 2016 Nov;162(11):1904-1912. doi: 10.1099/mic.0.000367. Epub 2016 Sep 22.

PMID:
27666313
6.

Erratum to "The implications of endemic IMP-4 carbapenemase for clinical laboratory susceptibility testing" [J. Microbiol. Methods 124 (2016) 10-12].

Goire N, Harnett GB, O'Reilly LC, Ingram PR, Leung MJ, Speers DJ, Healy PE, Inglis TJJ.

J Microbiol Methods. 2016 Sep;128:130. doi: 10.1016/j.mimet.2016.06.021. Epub 2016 Jul 6. No abstract available.

PMID:
27393044
7.

Tigecycline use in the outpatient parenteral antibiotic therapy setting.

Ingram PR, Rawlins MD, Murray RJ, Roberts JA, Manning L.

Eur J Clin Microbiol Infect Dis. 2016 Oct;35(10):1673-7. doi: 10.1007/s10096-016-2709-6. Epub 2016 Jun 20.

PMID:
27325439
8.

The implications of endemic IMP-4 carbapenemase for clinical laboratory susceptibility testing.

Goire N, Harnett GB, O'Reilly LC, Ingram PR, Leung MJ, Speers DJ, Healy PE, Inglis TJ.

J Microbiol Methods. 2016 May;124:10-2. doi: 10.1016/j.mimet.2016.03.001. Epub 2016 Mar 2. Erratum in: J Microbiol Methods. 2016 Sep;128:130.

PMID:
26945518
9.

Temporal flux in β-lactam resistance among Klebsiella pneumoniae in Western Australia.

Hall JM, Ingram PR, O'Reilly LC, Inglis TJJ.

J Med Microbiol. 2016 May;65(5):429-437. doi: 10.1099/jmm.0.000242. Epub 2016 Mar 4.

PMID:
26944048
10.

Genomic Characteristics of NDM-Producing Enterobacteriaceae Isolates in Australia and Their blaNDM Genetic Contexts.

Wailan AM, Paterson DL, Kennedy K, Ingram PR, Bursle E, Sidjabat HE.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):136-41. doi: 10.1128/AAC.01243-15. Print 2016 Jan.

11.

Photo Quiz: A 66-Year-Old Man With Severe Sepsis.

Hart J, Kruger P, Ingram PR.

J Clin Microbiol. 2015 Oct;53(10):3109, 3389. doi: 10.1128/JCM.02824-13. No abstract available.

12.

A comparison of paediatric and adult infectious diseases consultations in Australia and New Zealand.

Blyth CC, Walls T, Cheng AC, Murray RJ, Fisher DA, Ingram PR, Davis JS; Australasian Society for Infectious Diseases Clinical Research Network; Australian New Zealand Paediatric Infectious Diseases Research Network.

Eur J Clin Microbiol Infect Dis. 2015 Aug;34(8):1589-92. doi: 10.1007/s10096-015-2391-0. Epub 2015 Apr 29.

PMID:
25920492
13.

Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New Zealand.

Rogers BA, Ingram PR, Runnegar N, Pitman MC, Freeman JT, Athan E, Havers S, Sidjabat HE, Gunning E, De Almeida M, Styles K, Paterson DL; ASID CRN.

Int J Antimicrob Agents. 2015 Apr;45(4):351-8. doi: 10.1016/j.ijantimicag.2014.11.015. Epub 2015 Jan 13.

PMID:
25707371
14.

Appropriateness and determinants of antibiotic prescribing in an Australian emergency department.

O'Brien AP, Rawlins MD, Ingram PR.

Emerg Med Australas. 2015 Feb;27(1):83-4. doi: 10.1111/1742-6723.12346. Epub 2015 Jan 8. No abstract available.

PMID:
25627572
15.

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.

Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL.

Trials. 2015 Jan 27;16:24. doi: 10.1186/s13063-014-0541-9.

16.

Cutaneous mucormycosis and motor vehicle accidents: Findings from an Australian case series.

Ingram PR, Suthananthan AE, Rajan R, Pryce TM, Sieunarine K, Gardam DJ, Heath CH.

Med Mycol. 2014 Nov;52(8):819-25. doi: 10.1093/mmy/myu054. Epub 2014 Oct 6.

PMID:
25288654
17.

Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.

Manning L, Wright C, Ingram PR, Whitmore TJ, Heath CH, Manson I, Page-Sharp M, Salman S, Dyer J, Davis TM.

PLoS One. 2014 Jul 14;9(7):e102023. doi: 10.1371/journal.pone.0102023. eCollection 2014.

18.

Low vancomycin MICs and fecal densities reduce the sensitivity of screening methods for vancomycin resistance in Enterococci.

Wijesuriya TM, Perry P, Pryce T, Boehm J, Kay I, Flexman J, Coombs GW, Ingram PR.

J Clin Microbiol. 2014 Aug;52(8):2829-33. doi: 10.1128/JCM.00021-14. Epub 2014 May 28.

19.

Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis.

Pfister R, Kochanek M, Leygeber T, Brun-Buisson C, Cuquemelle E, Machado MB, Piacentini E, Hammond NE, Ingram PR, Michels G.

Crit Care. 2014 Mar 10;18(2):R44. doi: 10.1186/cc13760. Review.

20.

What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore.

Ingram PR, Cheng AC, Murray RJ, Blyth CC, Walls T, Fisher DA, Davis JS; Australasian Society for Infectious Diseases Clinical Research Network.

Clin Microbiol Infect. 2014 Oct;20(10):O737-44. doi: 10.1111/1469-0691.12581. Epub 2014 Mar 6.

21.

Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries.

Rogers BA, Ingram PR, Runnegar N, Pitman MC, Freeman JT, Athan E, Havers SM, Sidjabat HE, Jones M, Gunning E, De Almeida M, Styles K, Paterson DL; Australasian Society for Infectious Diseases Clinical Research Network.

Antimicrob Agents Chemother. 2014;58(4):2126-34. doi: 10.1128/AAC.02052-13. Epub 2014 Jan 27.

22.

A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia.

Coombs GW, Daley D, Pearson JC, Ingram PR.

Pathology. 2014 Jan;46(1):73-5. doi: 10.1097/PAT.0000000000000038. No abstract available.

PMID:
24300724
23.

Can interchangeability of lincosamides be assumed in clinical practice? Comparative MICs of clindamycin and lincomycin for Streptococcus pyogenes, Streptococcus agalactiae and Staphylococcus aureus.

Porter MC, Henderson BA, Healy PE, Coombs GW, Ingram PR, McLellan D, Clark B.

J Antimicrob Chemother. 2014 Mar;69(3):856-7. doi: 10.1093/jac/dkt436. Epub 2013 Oct 28. No abstract available.

PMID:
24164721
24.

Co-selection may explain high rates of ciprofloxacin non-susceptible Escherichia coli from retail poultry reared without prior fluoroquinolone exposure.

Ingram PR, Rogers BA, Sidjabat HE, Gibson JS, Inglis TJ.

J Med Microbiol. 2013 Nov;62(Pt 11):1743-6. doi: 10.1099/jmm.0.062729-0.

PMID:
24136884
25.

Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital.

Norton K, Ingram PR, Heath CH, Manning L.

J Antimicrob Chemother. 2014 Mar;69(3):805-8. doi: 10.1093/jac/dkt402. Epub 2013 Oct 9.

26.

Neutropenia is rare in patients receiving continuous infusions of vancomycin in an Australian Hospital in the Home setting.

Norton K, Ingram PR, Heath CH, Manning L.

Intern Med J. 2013 Aug;43(8):954-5. doi: 10.1111/imj.12213. No abstract available.

PMID:
23919343
27.

Potential utility for nomogram-based vancomycin dosing.

Elshaug EK, Manning L, Rawlins MD, Ridley BL, Ingram PR.

Int J Infect Dis. 2013 May;17(5):e355-6. doi: 10.1016/j.ijid.2012.11.007. Epub 2012 Dec 5. No abstract available.

28.

Stool culture.

Hewison CJ, Heath CH, Ingram PR.

Aust Fam Physician. 2012 Oct;41(10):775-9. Review.

PMID:
23210099
29.

Point-prevalence study of inappropriate antibiotic use at a tertiary Australian hospital.

Ingram PR, Seet JM, Budgeon CA, Murray R.

Intern Med J. 2012 Jun;42(6):719-21. doi: 10.1111/j.1445-5994.2012.02809.x.

PMID:
22697156
30.

Comparison of methods for AmpC β-lactamase detection in Enterobacteriaceae.

Ingram PR, Inglis TJ, Vanzetti TR, Henderson BA, Harnett GB, Murray RJ.

J Med Microbiol. 2011 Jun;60(Pt 6):715-21. doi: 10.1099/jmm.0.029140-0. Epub 2011 Mar 3.

PMID:
21372181
31.

Zoonotic tuberculosis: on the decline.

Ingram PR, Bremner P, Inglis TJ, Murray RJ, Cousins DV.

Commun Dis Intell Q Rep. 2010 Sep;34(3):339-41. Review.

32.

Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection.

Ingram PR, Inglis T, Moxon D, Speers D.

Intensive Care Med. 2010 Mar;36(3):528-32. doi: 10.1007/s00134-009-1746-3.

PMID:
20069274
33.

Latent tuberculosis infection in travelers: is there a role for screening using interferon-gamma release assays?

Ingram PR, Fisher DA, Wilder-Smith A.

J Travel Med. 2009 Sep-Oct;16(5):352-6. doi: 10.1111/j.1708-8305.2009.00315.x. Review. No abstract available.

34.

Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy.

Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH.

Int J Antimicrob Agents. 2009 Dec;34(6):570-4. doi: 10.1016/j.ijantimicag.2009.07.011. Epub 2009 Sep 9.

PMID:
19744837
35.

Acanthamoeba alternative oxidase genes: identification, characterisation and potential as antimicrobial targets.

Henriquez FL, McBride J, Campbell SJ, Ramos T, Ingram PR, Roberts F, Tinney S, Roberts CW.

Int J Parasitol. 2009 Nov;39(13):1417-24. doi: 10.1016/j.ijpara.2009.04.011. Epub 2009 May 21.

PMID:
19464295
36.

Induced encystment improves resistance to preservation and storage of Acanthamoeba castellanii.

Campbell SJ, Ingram PR, Roberts CW, Henriquez FL.

Parasitology. 2008 Oct;135(12):1401-5. doi: 10.1017/S0031182008005003.

37.

Limited role for outpatient parenteral antibiotic therapy for community-acquired pneumonia.

Ingram PR, Cerbe L, Hassell M, Wilson M, Dyer JR.

Respirology. 2008 Nov;13(6):893-6. doi: 10.1111/j.1440-1843.2008.01370.x.

PMID:
18811888
38.

Dengue management: practical and safe hospital-based outpatient care.

Ingram PR, Mahadevan M, Fisher DA.

Trans R Soc Trop Med Hyg. 2009 Feb;103(2):203-5. doi: 10.1016/j.trstmh.2008.07.007. Epub 2008 Aug 29.

PMID:
18760815
39.

Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.

Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA.

J Antimicrob Chemother. 2008 Jul;62(1):168-71. doi: 10.1093/jac/dkn080. Epub 2008 Mar 10.

PMID:
18334494
40.

Molecular basis for resistance of acanthamoeba tubulins to all major classes of antitubulin compounds.

Henriquez FL, Ingram PR, Muench SP, Rice DW, Roberts CW.

Antimicrob Agents Chemother. 2008 Mar;52(3):1133-5. Epub 2007 Dec 10.

41.

Comment on: Outpatient parenteral antibiotic therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years.

Ingram PR, Sulaiman Z, Chua A, Fisher DA.

J Antimicrob Chemother. 2008 Jan;61(1):226-7. Epub 2007 Nov 22. No abstract available.

PMID:
18033782
42.

Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.

Ingram PR, Howman R, Leahy MF, Dyer JR.

Clin Infect Dis. 2007 Jun 15;44(12):e115-7. Epub 2007 May 2.

PMID:
17516390
43.

Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba.

McBride J, Ingram PR, Henriquez FL, Roberts CW.

J Clin Microbiol. 2005 Feb;43(2):629-34.

44.

A comparison of the effects of ocular preservatives on mammalian and microbial ATP and glutathione levels.

Ingram PR, Pitt AR, Wilson CG, Olejnik O, Spickett CM.

Free Radic Res. 2004 Jul;38(7):739-50.

PMID:
15453639
45.

The interaction of sodium chlorite with phospholipids and glutathione: a comparison of effects in vitro, in mammalian and in microbial cells.

Ingram PR, Homer NZ, Smith RA, Pitt AR, Wilson CG, Olejnik O, Spickett CM.

Arch Biochem Biophys. 2003 Feb 1;410(1):121-33.

PMID:
12559984
46.

A COMPARATIVE INTRALUMINAL ONCOMETRIC STUDY OF THE EXPERIMENTALLY RECONSTRUCTED ESOPHAGOGASTRIC JUNCTION.

WILLIAMS GS, INGRAM PR.

Surg Gynecol Obstet. 1964 Jun;118:1205-16. No abstract available.

PMID:
14177832
47.

The experimental study of a new operation to restore esophagogastric competence and repair hiatus hernia.

INGRAM PR.

Surg Gynecol Obstet. 1963 Feb;116:203-11. No abstract available.

PMID:
13956535
48.

Direct measurement of the extracardiac collateral blood flow to the isolated coronary vascular bed.

LITTLEFIELD JB, INGRAM PR.

Surgery. 1962 Jul;52:32-6. No abstract available.

PMID:
14465908
49.

An experimental study of the use of exchanged citrated banked blood to prime an extracorporeal circuit.

INGRAM PR, LITTLEFIELD JB, MULLER WH Jr.

J Thorac Cardiovasc Surg. 1961 Jun;41:760-9. No abstract available.

PMID:
13717724
50.

A correlative histopathologic study of experimental surgical reflux esophagitis.

INGRAM PR, KESWANI RK, MULLER WH Jr.

Surg Gynecol Obstet. 1960 Oct;111:403-11. No abstract available.

PMID:
13717723

Supplemental Content

Loading ...
Support Center